FDA puts clinical hold on Selecta Biosciences SEL-302 phase 1/2 trial
Selecta Biosciences said that the US Food and Drug Administration (FDA) has imposed a clinical hold on its phase 1/2 clinical trial of SEL-302 gene therapy for the treatment of methylmalonic acidemia (MMA). SEL-302 consists of MMA-101 plus ImmTOR immune tolerance platform. The US-based biotech company said that it has been sent a letter from […]